Treatment Shortening of Drug-Sensitive Pulmonary Tuberculosis Using High Dose Rifampicin (Hi-DoRi-3)

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

926

Participants

Timeline

Start Date

September 30, 2020

Primary Completion Date

August 31, 2025

Study Completion Date

December 31, 2026

Conditions
Tuberculosis, Pulmonary
Interventions
DRUG

High-dose rifampicin

30mg/kg

DRUG

Isoniazid

300mg

DRUG

Pyrazinamide

20-30mg/kg

DRUG

Ethambutol

15-20mg/kg

DRUG

Rifampicin

10mg/kg

Trial Locations (1)

110-744

Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine and Lung Institute of Medical Research Center, Seoul National University College of Medicine, Seoul

All Listed Sponsors
collaborator

Chonnam National University Hospital

OTHER

collaborator

National Medical Center, Seoul

OTHER

collaborator

Pusan National University Hospital

OTHER

collaborator

Pusan National University Yangsan Hospital

OTHER

collaborator

Seoul National University Bundang Hospital

OTHER

collaborator

SMG-SNU Boramae Medical Center

OTHER

collaborator

Severance Hospital

OTHER

collaborator

Korean Institute of Tuberculosis

OTHER

collaborator

International Tuberculosis Research Center

OTHER

collaborator

Korean Center for Disease Control and Prevention

OTHER_GOV

lead

Seoul National University Hospital

OTHER